The White House said that US coronavirus task force response coordinator Deborah Birx will have a leading role in how Gilead Sciences' remdesivir will be distributed to hospitals, as reported in This is Money.
"She's the person who's constantly reviewing the numbers, constantly reviewing the data," said White House spokeswoman Kayleigh McEnany, adding that Birx "really has the best grasp as to how that should be distributed."
The federal government began distributing remdesivir this week, but doctors across the country, particularly in COVID-19 hotspots like New York and Boston, became concerned after being denied their request to obtain the new therapy, according to Thomas File, president of the Infectious Disease Society of America.
The physician group called on the Trump administration to explain how it will ensure equitable distribution of remdesivir to states and hospitals based on COVID-19 case and hospitalization rates.
To read more NewsPoints articles, click here.